文献速递免疫规划卫生政策与健康促进

疫苗供应:实现持续与广泛使用

Vaccine provision: Delivering sustained & widespread use.
PubMed 文献 · Vaccine · 2016-11-22

本文描述从候选疫苗临床开发到受种者接种的流程规模与复杂性,涉及生产质量控制(生产期间进行100至500项质量控制检测)、疫苗 presentation 选择与冷链维持,从概念到许可需10至30年,并提及应急加速途径与流感疫苗供应短缺问题。

要点

  • 生产期间进行100至500项质量控制检测以持续评估安全性、效价和纯度。
  • 从概念到许可需10至30年,许可基于向监管机构提交的综合文件。
  • 流感疫苗生产尤其具有挑战性,延迟可能导致流感季疫苗短缺。

核心结论

  • 疫苗从候选到受种者需经历复杂流程,最终目标是确保符合所需规格的免疫原性产品到达受种者。

研究设计与样本

  • 本文为综述,描述疫苗从临床开发到接种的流程规模与复杂性。

主要发现

  • 生产期间进行100至500项质量控制检测以持续评估安全性、效价和纯度。
  • 疫苗呈现形式(预充式注射器 vs 多剂瓶)的选择影响产能和供应。
  • 大多数疫苗有严格的储存温度要求以维持活性和效价。
  • 从概念到许可需10至30年。
  • 流感疫苗生产尤其具有挑战性,延迟可能导致流感季疫苗短缺,且因生产周期长和当地法规严格但各异而难以解决。

关键数值与推荐

  • 疫苗许可基于向监管机构提交的文件,包含化学、生产信息、检测程序、临床前和临床试验结果以及上市后有效性和安全性数据收集方案的综合汇编。
  • 在紧急情况下可寻求加速开发和许可途径,例如2009年H1N1流感大流行、2014年西非埃博拉疫情以及美国和新西兰的B群脑膜炎球菌性脑膜炎疫情。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The administration of a vaccine to a recipient is the final step in a development and production process that may have begun several decades earlier. Here we describe the scale and complexity of the processes that brings a candidate vaccine through clinical development to the recipient. These challenges include ensuring vaccine quality (between 100 and 500 different Quality Control tests are performed during production to continually assess safety, potency and purity); making decisions about optimal vaccine presentation (pre-filled syringes versus multi-dose vials) that affect capacity and supply; and the importance of maintaining the vaccine cold chain (most vaccines have stringent storage temperature requirements necessary to maintain activity and potency). The ultimate aim is to make sure that an immunogenic product matching the required specifications reaches the recipient. The process from concept to licensure takes 10-30years. Vaccine licensure is based on a file submitted to regulatory agencies which contains the comprehensive compilation of chemistry, manufacturing information, assay procedures, preclinical and clinical trial results, and proposals for post-licensure effectiveness and safety data collection. Expedited development and licensure pathways may be sought in emergency settings: e.g., the 2009 H1N1 influenza pandemic, the 2014 West African Ebola outbreak and meningococcal serogroup B meningitis outbreaks in the United States and New Zealand. Vaccines vary in the complexity of their manufacturing process. Influenza vaccines are particularly challenging to produce and delays in manufacturing may occur, leading to vaccine shortages during the influenza season. Shortages can be difficult to resolve due to long manufacturing lead times and stringent, but variable, local regulations. New technologies are driving the development of new vaccines with simplified manufacturing requirements and with quality specifications that can be confirmed with fewer tests. These technologies could have far-reaching effects on supply, cost of goods, and on response timing to a medical need until product availability.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Preiss S, Garçon N, Cunningham AL, et al. Vaccine provision: Delivering sustained & widespread use. Vaccine. 2016. PMID: 27884478. doi:10.1016/j.vaccine.2016.10.079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。